YanyanLouMD

Physician

Dr. Lou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2009 - 2012
Zhengzhou UniversityClass of 1997

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients Start of enrollment: 2022 Aug 01
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments Start of enrollment: 2019 Oct 01
Recruiting
Roles: Contact, Principal Investigator

PubMed

Osimertinib and Cardiotoxicity: A Topic to Keep Addressing.
Shenduo Li, Rami Manochakian, Yujie Zhao, Yanyan Lou
Journal of Thoracic Oncology. 2025-02-01
A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors.
Aurora Norman, Mahesh Seetharam, Jacob Allred, Jianping Kong, Mateusz Opyrchal
BJC Reports. 2025-01-14
FES avid pulmonary adenocarcinoma and confounding ER+ breast carcinoma.
Yousif M Abdelmoneim, Yanyan Lou, Pooja Advani, Andras Khoor, Akash Sharma
Radiology Case Reports. 2025-01-01

Pharmacists Play Key Role in Clinical ResearchMay 19th, 2023
Mayo Clinic in Jacksonville Offers Advanced Program for Mesothelioma TreatmentApril 29th, 2021
Study Cites Race and Socioeconomic Factors as Influential in NSCLC Patient Survival RatesOctober 16th, 2017
Join now to see all